HBW-3-20

N/A

Report date: 2022/05/19 17:54:57
NME

Base Information

Drug NameHBW-3-20
Drug Alias NameHBW-3-20HBW-003
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHyperway Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHyperway Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A